We are submitting outcome of Board Meeting held on August 13, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech's board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025), with auditors A N S K & Associates issuing an unmodified (clean) review report. On a standalone basis, revenue from operations rose about 7.8% year-on-year to Rs. 4,649.64 lakhs and profit after tax grew around 8.1% to Rs. 616.08 lakhs, with EPS at Rs. 7.46. Consolidated net profit after tax stood at Rs. 686.28 lakhs (including Rs. 70.20 lakhs share from associates Peptech Biosciences and Titan Media), translating to EPS of Rs. 8.30. The board appointed Mr. Debendra Kumar Sabat as an Additional Independent Director and re-appointed Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla as Managing Directors for a fresh five-year term from April 1, 2026 to March 31, 2031, subject to shareholder approval. The 33rd AGM is scheduled for September 26, 2025 via video conferencing, with September 19, 2025 fixed as the record date for a recommended final dividend of Rs. 2.00 per equity share.
Results show steady, modest single-digit growth in both revenue and profits with a clean auditor's opinion, which is neutral-to-mildly positive for shareholders. The continuity of the promoter-led management team, final dividend of Rs. 2 per share, and new independent director add to governance stability ahead of the AGM.